Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets cancer enzyme in early human trial

NCT ID NCT06911008

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called MTI-301 in 42 adults with advanced solid cancers that have spread or can't be removed and haven't responded to standard treatments. The drug blocks an enzyme called SCD1, which some cancers use to grow and spread. The main goals are to find the safest dose and check for side effects, while also seeing if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MTI-301 (a drug that blocks the SCD1 enzyme, which may slow tumor growth)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid cancers that have stopped responding to other therapies.
What could go wrong
This is a very early Phase I trial with only 42 people, focused mainly on safety and dosing. The drug may not shrink tumors or could cause side effects, and it's too soon to know if it will help patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm neoplasm Neoplasm Metastasis refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC MALIGNANT SOLID NEOPLASM REFRACTORY MALIGNANT SOLID NEOPLASM UNRESECTABLE MALIGNANT SOLID NEOPLASM

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.